Please read these articles
http://boards.fool.co.uk/Message.asp?mid=7842473

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

http://www.medisys-group.com/Prelims_5_061202-1.pdf'

http://www.safetysyringesplus.com/info.htm

This has massive potential from products other than FUTURA which if it takes off will be the iceing on the cake.Let me give you the highlights from this Mays interims;

Financial Highlights

Financial performance improved significantly:

* Turnover increased by 9% to #20.1 million (2002: #18.4 million)

* Product sales increased by 25% on a constant US dollar exchange rate basis

* Earnings before interest, tax, depreciation and amortisation was #0.3
million (2002: EBITDA loss of #7.0 million, before exceptional items, as
restated)

* Gross margin 37% (2002: 33%)

* Selling, distribution and administration costs reduced to #4.8 million
(2002: #7.4 million before exceptional items)

* Profit before amortisation and research and development expenditure
#2.6 million (2002: loss of #0.8 million before exceptional items)

* Research and development expenditure #3.0 million (2002: #7.1 million,
as restated)

* Operating loss #1.3 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss before tax #1.6 million (2002: #9.2 million, before exceptional
items, as restated)

* Loss per share 0.58p (2002: 2.58p, before exceptional items, as
restated)

Product Highlights

* Sales of existing products in line with expectations

- Sales of Assure range increased to #6.9 million (2002: #5.6 million)

- QuickTek sales to mail order market segment #2.6 million

- Sales of Futura Safety Scalpel #1.0 million in period

- Sales of Advance system #0.5 million in period

* Futura Safety Syringe and Flight disposable blood glucose monitoring
system remain on track for mid-2003 market launch

* Development of Spear capillary fill bio-sensor strip proceeding to
schedule.

Pretty impressive eh !!

Now since this we have had;

FDA approval for Hypogaurd

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=4778825&symbol=LSE%3AMDY

Futura passing final quality tests with Smiths

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5023328&symbol=LSE%3AMDY

A partnership with Walmart for Flight

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5194692&symbol=LSE%3AMDY

Launch of Spear

http://www.advfn.com/p.php?pid=nmona&cb=1064066532&article=5250424&symbol=LSE%3AMDY

Medisys "buy"

Monday, September 29, 2003 8:28:27 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) Analyst I Broadhurst of Dryden Financial issues a "buy" rating on Medisys (MDY.L).

2003 New Ratings

Now this looks to me a company growing rapidly.The more I look into MDY the more confident I become of the potential rewards.These will not be instantaneous but will come over a period of time.Look at the turnaround in those figures posted above.Now that was in a recession.

http://www.charles-stanley.co.uk/content/SMI_oct03.pdf (see page 4)

http://www.research.reuters.co.uk/Research/Earnings.asp?ticker=MDY.L&country=GB&mxid=100068815&companyName=MEDISYS+PLC&sym=RE
VERY IMPORTANT MESSAGE TO ALL BUYERS/HOLDERS - PLEASE LISTEN

http://www.wallstreetreporter.com/profiles/Medisys.html

Scottie SIT there's a good BOY !

SOme people dont fully understand the potential returns on offer here !

Scottie, if you're not into this, why waste your time (and ours) posting useless statements?

This is why people will invest in MDY !

Jenniferzz - 6 Mar'04 - 10:26 - 5093 of 5096


LONDON (AFX) - Tadpole Technology PLC year to September 30 2003
Sales on continuing ops - 3.57 mln stg vs 1.84 mln
Pretax loss - 9.57 mln stg vs loss 11.14 mln
Loss per share - 4.3 pence vs LPS 5.7

TAD MKT CAP 54 Million, sales 3.57 million, 9.57 million loss

LONDON (AFX) - Medisys PLC year to September 30 2003
Sales - 39.59 mln stg vs 35.72 mln
Pretax loss before exceptionals - 2.50 mln stg vs loss 19.58 mln
Pretax profit before exceptionals and goodwill - 4.1 mln stg vs loss 2.5mln
Pretax loss - 5.68 mln stg vs loss 32.99 mln
Operating loss before exceptional - 1.99 mln stg vs loss 19.52 mln
Operating loss - 5.51 mln stg vs loss 31.82 mln
EBITDA - 1.1 mln stg vs loss 14.8 mln
Loss per share before exceptionals - 0.97 pence vs LPS 5.37
Loss per share - 1.78 pence vs LPS 8.85

MDY MKT CAP 42 Million, sales 39.59 million, EBITDA positive

Compare TAD or a mulititude of others with MDY and MDY is far better
value and any growth story scenario is dismissed and should the Queens huskies fart in her lounge at the weekend then this is certain to result in a mark down in the MDY share price. The value of this company will be borne out and a significant higher value or a takeover of the business is inevitable.

According to the last paragraph look for some more new products to boost sales later !!

New Retractable Syringe from Medisys


Pharmacy Today

The UK company Medisys, in an effort to conform to new US laws protecting medical staff from needle-stick accidents, has developed a hypodermic syringe with retractable needle. Medisys' Futura syringes have an automatic retractable needle that retracts into the syringe when the hypodermic plunger is fully depressed. They are expected to be on the market later this year.


Stricter US laws are a reaction to the 800,000 needle-stick injuries that occur annually in the US, all of which have the potential of spreading the human immunodeficiency virus (HIV) or hepatitis. It is increasingly likely that these stricter laws and regulations will be replicated in Japan, Singapore, and other countries.


The retractable technology of the Futura syringe is the core of Medisys' safety development measures, which are exploited in a number of other products. The company also expects to release a safety catheter with a retractable needle mechanism within the next 18 months.

Shipments to Walmart beggining !!

Parlex To Add Greater Value On Computer & Medical Projects

METHUEN, Mass.--(BUSINESS WIRE)--March 3, 2004--Parlex Corporation announced today that two major customers have qualified Parlex to provide additional assembly services on flexible circuits they currently supply. As a major supplier to the inkjet printer market, Parlex will now place surface mount components on many of the products it manufactures. Component attachment will utilize Parlex's patented, lead free adhesive, Polysolder(R). Based on customer projections, this additional scope could add up to $4 million to its computer segment sales over the next 12 months. In the medical market, Parlex has been a supplier of glucose monitoring test strips for the past 15 months. Our customer, Hypoguard, the diagnostic division of Medisys PLC, has qualified Parlex to produce a fully integrated glucose monitoring system with 100 pre-calibrated test strips in a disposable pre-loaded meter. Parlex anticipates that this transition will more than double the unit value of our product. Shipments are scheduled to commence in the next few weeks.


Peter J. Murphy, Parlex President and CEO stated, "It is clear that moving up the value chain should accelerate revenue growth and strengthen relationships with our customers. We believe that our ability to offer the widest range of flexible interconnect products, including value added products, will enhance our position in the marketplace. The Company currently has an added value element on approximately 30% of our business; our goal is to increase this to over 50% by year end."

About Parlex Corporation

Parlex Corporation is a world leader in the design and manufacture of flexible interconnect products. Parlex produces custom flexible circuits and laminated cables utilizing proprietary processes and patented technologies, which are designed to satisfy the unique requirements of a wide range of customers. Its manufacturing facilities are located in the United States, China, Mexico and the United Kingdom.

The foregoing contains certain forward-looking statements. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of various factors beyond its control, including economic conditions in the electronics industry, particularly in the principal industry sectors served by the Company, changes in customer requirements and in the volume of sales to principal customers, competition and technological change. For a detailed discussion of these and other cautionary statements, please refer to Parlex's filings with the Securities and Exchange Commission.

A great post worth sharing !

Author german bite View Profile | Add to favourites | Ignore
Date posted today 12:26
Classification Comment
Subject: My Reasons
Opinion Strong BUY
Recommendations This message has been recommended 10 times, including by you
Message


********************

Those of us that are involved with the stock market know that is not an exact science in so far as valuations v's the share price of a quoted company are concerned. Indeed we all know of companies that over the years have been OVERVALUED or UNDERVALUED in relation to the company/underlyeing business a direct opposite to what the share price (market cap) was saying at the time.

I start off by saying that some of the "previous" managements decisions/deals/rational "appear" to have been, to put it mildly, very poor, but I HONESTLY BELIEVE those days are behind us and the company under the CEO David Conn, is now in good hands.

So lets have a look at MEDISYS basic core business which it SHOULD be VALUED on today:

TURNOVER: 2001 2002 2003

20.9mm 35.7m 39.1m

All well and good but what about costs such as Admin,Sales and Distribution?

SALES and DISTRIBUTION COSTS:

27% of REVENUE 2001 20% of REVENUE 2002 12% of REVENUE 2003

ADMIN COSTS:

21% of REVENUE 2001 18% of REVENUE 2002 13% of REVENUE 2003

RESEARCH and DEVELOPEMENT:

23% of REVENUE 2001 38% of REVENUE 2002 12% of REVENUE 2003

NOTE:As you can see a MASSIVE amount of money was spent on R and D (2002)mainly due to getting the FUTURA SAFETY SYRING and NEWTEK (Wal Mart)monitor ready.Now that they are ready for market less R and D expenditure is incured as you can see by the fall in 2003!
____________________

Worth noting at this point that Diabetes Monitors are "sold at a loss" by all companies and the profit is gained from subsequent sales of the "test strips".So if a NEW monitor is brought to market,innitialy it hits costs for little return.HOWEVER the new monitor we have invented and are bringing to market via WAL MART is an ALL in ONE that has test strips built in so will be sold with an IN BUILT PROFIT MARGIN at point of sale.

______________________

Were are our markets:?

TURNOVER:

UK 2.944m 2001 1.53m 2002 0.433k 2003

US 26.49m 2001 34.11m 2002 36.74 2003.

OTHER 0.464k 2001 0.730k 2002 1.943m 2004.

From the above I looked at the LOSS on the UK business of 13.37m in 2002 and a LOSS of 3.451m in 2003 to ALLOW for the possibility that we will, at some point, become just a USA company either quoted on the NasdaQ or simply bought out by a USA based company.

CLASS of BUSINESS TURNOVER:

DIAGNOSTICS : 23.17m in 2002 31.12m in 2003.

HEALTH SAFETY PRODUCTS 4.027m in 2002 3.86m 2003.

This gives us our "core" market.I would like to point out at this stage the reasons I am not "worried to death" about ROCHE.

Medisys have declared they are indemnified by Apex,however we do not know at this stage how "wide"

Make no mistake it is not ideal.From this point we have to make some MASSIVE assumptions and other less so large ones!

Firstly, there has to be MERIT in ROCHES claims.

Secondly they have to prove this.

Thirdly, they have to WIN in a court of law.

So ASSUMING the worst, MEDISYS have to stop selling the ASSURE meters,well we DO HAVE OTHERS but how hard is it to replace a best seller??

This is a run down of MEDISYS previous FLAGSHIP betselling monitor the SUPREME that is casually and very successfully being replaced by our other monitors.

SALES of SUPREME:

2001 10.5m 2002 7.6m 2003 4.2m

My point being, if MEDISYS can REPLACE the above monitor so successfully in such a relatively "short" time span when there is no RUSH, imagine what they could do if they needed to "transfer" old ASSURE users over to NEWTEK,QUICKTEK or ADVANCE meters!

To some up the company under David Conn have cleaned up the books with MASSIVE write offs the put a line under past "management mistakes"

They have REDUCED Sales and Distribution costs:

They have REDUCED Administration costs:

They have REDUCED R + D costs, yet still keep a healthy spend of approx (on my expected 2004 numbers) of around 11% of TURNOVER,to show that more NEW PRODUCTS are in the pipeline, after all this is the FUTURE REVENUE.

They have INCREASED Turnover.

They have increased Gross Profit

They HAVE IMHO already taken us (as results will prove interims March 2004)into MAIDEN profit.

This is without ONE PENNY of revenue from either the FUTURA SAFETY SYRINGE or NEWTEK.
**************

I FULLY take on board the markets at this moment in time do not like MEDISYS or its past management mistakes or unforfilled promises but there WILL come a point were the UNDERLYING real tangible proven (in the accounts) VALUE and WORTH of this company will shine like a beacon for anyone that cares to look.

If the institutions choose to continue to ignore us and refuse to walk toward the light, then there is a VERY REAL chance IMHO of EITHER a TAKE OVER, MBO or going private or as mentioned before QUITING the UK altogether for the US markets who are more aquainted with our HYPOGUARD arm/brand anyway.

How base market place is growing all over the world.Our REACH will grow along with Wal Mart (and other partnerships we "actively seek")and barring an overnight "cure" for diabetes (equal too petrol not being needed overnight, so Shell better watch out!)no matter what happens to an extent to acconomies,DIABETES is growing and the need for our products grows by the day too.

What ever happens,I HONESTLY believe that my INVESTMENT in this company will REPAY me handsomely in the FUTURE for my faith and patience.


GB (Lisa279)

Medisys shares jump on syringe launch
Mon 22 March, 2004 08:56
RELATED REPORTS
MDY.L Profile Report
Business description, 3yr and interim financials, key stats/ratios & analysis.
| 12 pages | 10 | Details


LONDON (Reuters) - Shares in Medisys have leapt as much as 26 percent after the medical devices firm said it had launched its long-delayed Futura Safety Syringe in the United States and received its first big order.

At 8:35 a.m. on Monday, the shares MDY.L were up 23.8 percent at 13 pence, off an early high of 13-1/4p and valuing Medisys at about 53 million pounds.

The Futura Safety Syringe, whose needle retracts to stop hospital staff from pricking themselves, was originally planned for launch more than two years ago, but was dogged by testing delays and an argument between Medisys and the firm's original distribution partner, Smiths Group SMIN.L .

Medisys sacked Smiths in September after that firm's chief executive, Keith Butler-Wheelhouse, was quoted in a newspaper as saying he had "almost given up" on the Futura Safety Syringe.

Medisys said it had launched the syringe through its own 40 person sales and marketing team and won its first big order from an unnamed medical products distributor in the United States.

It also said it was continuing to explore a potential major distribution partnership.

Bet you wish you hadn't sold out now chickens!!!

Onwards and upwards with futura leading the way.

LOL !

I'm am actually now getting very excited by MDY ! Why ?

Well when the stock market was down heavily the share was trading as high as 26p.News of the split with Smiths and the patent problem have driven the price down 50% !

The Futura issue which everyone has been waiting for has now been resolved and lets just anticipate that the news on the patent front is unfounded.During this downtime we also went EBITDA positive.

Now those factors alone should really see us moving back to the recent highs if not higher and with the possibility of additional good news we could all be looking at a very Merry Christmas.

And it helps if you bought more at the depressed prices like I had the kahunas to do!

Roll on 20p, 30p, 40p, etc, etc (ramp away until my eyes bleed!!!!!)

We just need to hear that a major international distribution company has come on board for this to sky rocket IMHO. Then we can wait in anticipation for the full results after all the products are on line and rolling off the shelves! NICE!!!!

AGM this week ?

Thursday Happy1 :)

Gotta be more good news at the AGM. I'm hoping the Smiths debacle did not effect earnings and turnover too much. Did Mdy ever see the cash Smiths owed them for the contract termination?

Roll on tomorrow!

Looking very good today.After a 28% rise we had a bit of profot taking and are now firmly into an upward trend.

RNS Number:9201W
Medisys PLC
25 March 2004



For Immediate Release 25 March 2004


Medisys PLC
("Medisys" or "the Group")


FirstOrder For NewTek Blood Glucose Monitor Received From Wal-Mart


Further to the AGM Statement released earlier today, Medisys announces that it
has now received the first purchase order for its NewTek product from Wal-Mart,
the Group's exclusive USretail partner for the product.


The purchase order was received overnight and will be fulfilled from existing
inventory. It is anticipated that shipping will commence today.


Dave Conn, Chief Executive, commented: "The receipt of our first order from
Wal-Mart is a major milestone for the Group. NewTek is the first ever fully
integrated, disposable blood glucose monitoring system offering a new level of
convenience to the user. We are excited by its prospects as part of Wal-Mart's
well established ReliOn(R) brand, which offers value based products to their
diabetes customer."


- Ends -

Enquiries:


Medisys PLC 020 7563 5200
David Conn, Chief Executive Officer

Michael Barry, Chief Financial Officer

A very robust defence claim to the Roche problem !

Now we are opening up the diabetese market into Europe.Massive new revenue channels !

Moving into Europe today ! The good news just keeps on coming !!!http://www.uk-wire.com/cgi-bin/articles/200404300700111754Y.html

We also have interims comming up and the $ has been strengthening against sterling. This will soon have a re-rating IMO.

Another snippet of news is that NMT have sorted the patent claim with RTI but are now unable to sell in the USA.Who will Roche now use ?

Less competition.Let the good times roll !